Midatech Pharma PLC (MTP)
|Net Income (ttm)||-30.40M|
|Trading Day||May 13|
|Day's Range||1.98 - 2.08|
|52-Week Range||1.23 - 7.07|
Preliminary Results for the Year Ended 31 December 2020 ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 30, 2021 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), a drug delivery technology company focused o...
Non-binding Heads of Terms for Co-development of MTX110; Unaudited Headline Results for the Year Ended 31 December 2020 ABINGDON, UK / ACCESSWIRE / March 25, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASD...
Midatech Pharma (MTP) news for Monday includes positive results from a Phase I study of a DIPG treatment boosting MTP stock higher. The post Midatech Pharma News: Why MTP Stock Is Surging 10% Today appe...
Midatech Pharma plc (MTP) CEO Craig Cook on Q2 2020 Results - Earnings Call Transcript
Midatech Pharma (MTP) news for Friday includes talk from the company about reselling roughly 12.7 million shares pushing MTP stock higher. The post Midatech Pharma News: Why MTP Stock Is Soaring 56% Tod...
Midatech Pharma (MTP) news for Tuesday concerning a collaboration deal involving the Q-Sphera platform has MTP stock taking off. The post Midatech Pharma News: Why MTP Stock Is Skyrocketing 154% Today a...
A stronger diabetes vaccine may be what the doctor will order soon as Midatech Pharma's clinical trial were "positive." MTP stock is up.
Midatech Pharma PLC-ADR (NASDAQ: MTP) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate...
The U.S.-listed shares of Midatech Pharma PLC rocketed 113% on very heavy volume in premarket trading Friday.
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere micro... [Read more...]
|Stock Exchange |
|Ticker Symbol |
In 2020, MTP's revenue was 343,000, a decrease of -49.11% compared to the previous year's 674,000. Losses were -22.19 million, 120.0% more than in 2019.